Clinical trials: Proton Pump Inhibitor, open to volunteers
Laryngopharyngeal Reflux Disease
Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease
The goal of this randomized controlled trial is to compare the effectiveness of different treatments for laryngopharyngeal reflux disease (LPRD) in adult patients with confirmed symptoms and signs of the condition.
- Trial name
- NCT07611162
- Testing
- Alginate, Magaldrate, Sucralfate
- Where
- Belgium
- Volunteers
- 800 people
- Sponsor
- University of Mons
HIV, Inhaled Corticosteroid
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy.
- Conditions
- HIV, Inhaled Corticosteroid, Proton Pump Inhibitor, Smoking Cessation
- Trial name
- NCT07507435
- Testing
- E-consult
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Gastroesophageal Reflux, Infant, Newborn, Diseases
Treatment of Gastroesophageal Reflux Disease in Infants
Gastroesophageal reflux disease in infants is not fully understood. Infants are prescribed medical treatments that may not be effective or that contribute to adverse side effects and lead to concerns and expenses for the parents…
- Trial name
- NCT06255886
- Testing
- Protein pump inhibitor., Mother or infant diet
- Where
- 3 sites in Denmark
- Volunteers
- 96 people
- Sponsor
- Odense University Hospital
Acute Kidney Injury
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation…
- Trial name
- P2 AKI PPI (NCT06706258)
- Testing
- Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- The University of Texas Health Science Center, Houston
Malignant Gastric Outlet Obstruction
Prophylactic PPI Use After EUS-GE Procedure
This study aims to compare the 6-month cumulative incidence of mucosal erosion or ulcer involving the anastomosis and LAMS flange in patients with and without 6-month prophylactic PPI treatment following EUS-GE, and to assess…
- Trial name
- NCT07896577
- Testing
- Esomeprazole
- Volunteers
- 273 people
- Sponsor
- Changhai Hospital
Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease
Oral Fosamprenavir for GERD
The goal of this clinical trial is to learn if study drug Fosamprenavir administered orally improves symptoms for Proton Pump Inhibitor (PPI)-refractory Gastro Esophageal Reflux Disease (GERD).
- Trial name
- NCT06704100
- Testing
- Fosamprenavir Calcium 700 MG Oral Tablet
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical College of Wisconsin
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Inappropriate Prescribing, Implementation Science
Reduction of Low-value Prescribing Through Audit and Feedback
The objective is to estimate the effect attributable to a primary care pharmacist-led audit and feedback (AF) strategy compared to the currently used AF strategy as a management tool to evaluate healthcare performance focusing on…
- Conditions
- Inappropriate Prescribing, Implementation Science, Behavioral Sciences
- Trial name
- AFFAP (NCT07336550)
- Testing
- Usual AF, Facilitated AF
- Where
- Spain
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Basque Health Service
GERD (Gastroesophageal Reflux Disease)
A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures
Medication non-adherence is associated with greater morbidity and mortality in chronic disease, and has been estimated to increase healthcare costs by over $170 billion annually in the United States.1 Medication adherence is…
- Trial name
- NCT07712614
- Testing
- Fortiskap
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cosmos Rx, Inc
GERD in Infants
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
The goal of this investigator-initiated, single-center, randomized controlled trial (RCT) is to compare the effects of four weeks of three therapies on clinical and mechanistic outcomes based on pH-Imp testing using a three-arm…
- Trial name
- GIFT (NCT06114836)
- Testing
- Omeprazole, AR formula
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Nationwide Children's Hospital
GI Bleeding
High Dose Oral Omeprazole in High Risk UGIB
Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world. After endoscopic treatment, proton pump inhibitor (PPI) is recommended to prevent re-bleeding.
- Trial name
- NCT04394663
- Testing
- High-dose oral omeprazole, Standard IV PPI
- Where
- 2 sites in Thailand
- Volunteers
- 128 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Potassium-Competitive Acid Blocker, Proton Pump Inhibitor
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori…
- Conditions
- Potassium-Competitive Acid Blocker, Proton Pump Inhibitor, Bismuth Based Quadruple Therapy, Treatment
- Trial name
- NCT07165444
- Testing
- Potassium-Competitive Acid Blocker, Proton Pump Inhibitor
- Where
- Egypt
- Volunteers
- 320 people
- Sponsor
- Tanta University
Morbidity
PPIs and In-Hospital Morbidity in Acute Variceal Bleeding With Chronic Liver Disease
With this study, the investigators pretend to describe intrahospital morbidity in patients living with cirrhosis (PLC) who present to the emergency department with variceal bleeding (VB).
- Trial name
- Liver-IMPACT (NCT06861478)
- Testing
- Omeprazole 40 mg IV, pantoprazole 40 mg iv
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Inappropriate Prescribing, Reflux Disease
Deprescribing Inappropriate Proton Pump Inhibitors
The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting.
- Conditions
- Inappropriate Prescribing, Reflux Disease, Proton Pump Inhibitors
- Trial name
- DROPIT (NCT06129474)
- Testing
- Proton Pump Inhibitor deprescribing tool
- Where
- 2 sites in Switzerland
- Volunteers
- 400 people
- Sponsor
- University of Bern
HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity.
- Conditions
- HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection, Helicobacter Pylori Infected Patients
- Trial name
- NCT07293910
- Testing
- Vonoparazan, Vitamin D, Probiotic
- Where
- Egypt
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Tanta University
Healthy
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in…
- Trial name
- NCT05517928
- Testing
- Omeprazole, Lactobacillus rhamnosus GG
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy Adult
Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants
This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults.
- Trial name
- NCT07550946
- Testing
- VRN101099
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Voronoi, Inc
Esophageal and Gastric Varices, Liver Cirrhosis
Pantoprazole After Prophylactic Endoscopic Variceal Treatment
Traditionally, it is considered that gastric acid delays ulcer healing, and acid suppression can reduce the risk of post-banding ulcer bleeding and promote mucosal healing at the ulcer site.
- Trial name
- NCT07248722
- Testing
- Pantoprazole
- Where
- China
- Volunteers
- 208 people
- Sponsor
- General Hospital of Shenyang Military Region
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants
This study will look at how two commonly used medicines, omeprazole and cyclosporine, influence the way the body absorbs, processes, and eliminates velzatinib in healthy volunteers.
- Trial name
- NCT07862114
- Testing
- Velzatinib, Cyclosporine, Omeprazole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Proton Pump Inhibitors, Human Gastrointestinal Tract
Intestinal Microbiota After PPI Treatment
This clinical study aims to investigate the effects of short-term treatment with proton pump inhibitors (PPIs) on the gut microbiota of pediatric patients.
- Conditions
- Proton Pump Inhibitors, Human Gastrointestinal Tract, Gastroesophageal Reflux Disease
- Trial name
- PPI (NCT07036627)
- Testing
- study of microbiota
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bari